

## Ravagalimab

Cat. No.:	HY-P99821
CAS No.:	2050816-56-1
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Ravagalimab (ABBV-323) is a CD40 antagonist (EC <sub>50</sub> : 3.7 nM). Ravagalimab can be used for research of Crohn's disease <sup>[1]</sup> .
IC <sub>50</sub> & Target	CD40 3.7 nM (EC <sub>50</sub> )
In Vitro	Ravagalimab (0-100 nM, 2 days) inhibits CD86 upregulation on primary human B cells with an EC <sub>50</sub> of 0.6 nM <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29.
- [2]. Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37(6):850-866.e7.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA